New drug targets Hard-to-Treat cancers in early trial

NCT ID NCT07083323

Recruiting now Disease control Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called HY05350 in people with advanced solid tumors that have a protein called MSLN on their surface. The trial has two parts: first, finding a safe dose, and second, seeing if the drug shrinks tumors. About 262 participants who have exhausted standard treatments will receive the drug intravenously on a weekly or biweekly schedule.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HY05350 (an investigational drug given intravenously)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific marker (MSLN) and have not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or may have significant side effects. It is also only for patients with MSLN-positive tumors, limiting who can benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Peking University Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.